DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LANSOPRAZOLE

« Back to Dashboard

All Clinical Trials for Lansoprazole

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00149084	Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori	Unknown status	Yokoyama Foundation for Clinical Pharmacology	Phase 3	2003-04-01	The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The investigators intend to investigate whether the tailored therapy based on the two above-mentioned factors increases the cure rate of the initial eradication therapy.
NCT00149084	Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori	Unknown status	Hamamatsu University	Phase 3	2003-04-01	The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The investigators intend to investigate whether the tailored therapy based on the two above-mentioned factors increases the cure rate of the initial eradication therapy.
NCT00174928	A Study to Evaluate the Effect of Lansoprazole on Hospitalized Neonates With Gastroesophageal Reflux Disease	Completed	Takeda	Phase 1	2005-05-01	The purpose of this study is to understand how quickly lansoprazole, once daily (QD), improves feeding in premature babies or babies less than 28 days of age.
NCT00175032	A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose Aspirin	Completed	Takeda	Phase 3	2003-07-01	The purpose of this study is to compare the gastroduodenal ulceration rate, gastrointestinal complication rate and non-steroidal anti-inflammatory drug-associated dyspepsia between lansoprazole, naproxen and celecoxib, taken once daily (QD) or twice daily (BID), in participants with osteoarthritis taking low dose aspirin.

Clinical Trial Conditions for Lansoprazole

Condition Name

Condition Name for Lansoprazole
Intervention	Trials
Healthy	13
Gastroesophageal Reflux Disease	10
Erosive Esophagitis	10
Helicobacter Pylori Infection	10

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Lansoprazole
Intervention	Trials
Gastroesophageal Reflux	27
Esophagitis	18
Ulcer	16
Helicobacter Infections	15

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Lansoprazole

Trials by Country

Trials by Country for Lansoprazole
Location	Trials
United States	279
Japan	271
China	68
Korea, Republic of	26
Taiwan	18

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Lansoprazole
Location	Trials
Missouri	13
California	13
Texas	12
Florida	12
Ohio	11

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Lansoprazole

Clinical Trial Phase

Clinical Trial Phase for Lansoprazole
Clinical Trial Phase	Trials
Phase 4	45
Phase 3	42
Phase 2/Phase 3	2

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Lansoprazole
Clinical Trial Phase	Trials
Completed	79
Recruiting	22
Not yet recruiting	14

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Lansoprazole

Sponsor Name

Sponsor Name for Lansoprazole
Sponsor	Trials
Takeda	35
AstraZeneca	10
National Taiwan University Hospital	5

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Lansoprazole
Sponsor	Trials
Other	108
Industry	83
NIH	3

Export unavailable in trial.
Subscribe for complete access.